DelveInsight’s analysis indicates that the Gastrointestinal Stromal Tumors (GIST) pipeline involves over 25 key companies actively developing more than 28 therapies for GIST treatment.
Gastrointestinal Stromal Tumors Overview:
Gastrointestinal Stromal Tumors (GISTs) are a type of sarcoma, a group of malignant tumors arising from connective tissues such as fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This distinguishes sarcomas from other cancers: carcinomas develop in the lining of organs or tissues (e.g., lungs, colon, breast, prostate, pancreas), lymphomas originate in immune cells within lymph nodes, and leukemias arise from immune cells in the bone marrow.
GISTs can produce a variety of symptoms, including nausea, early satiety, bloating, and unexplained weight loss. Physical signs may include anemia or a detectable abdominal mass. The type and severity of symptoms depend on the tumor’s location (such as the stomach or rectum), size, and growth pattern.
Download our report @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
“Gastrointestinal Stromal Tumors Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Gastrointestinal Stromal Tumors Therapeutics Market.
Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Report
DelveInsight’s Gastrointestinal Stromal Tumors (GIST) pipeline report highlights a vibrant landscape, with over 25 active companies developing more than 28 therapies for GIST treatment.
Recent FDA approvals include:
-
May 2020: Ripretinib was approved for adults with advanced GIST who have previously received three or more kinase inhibitors, including imatinib, serving as a fourth-line treatment option.
-
January 2020: Avapritinib was approved for adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including the D842V mutation, representing the first targeted therapy for this specific genetic alteration.
Key companies involved in GIST drug development include Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, DNAtrix, Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, and others.
Notable pipeline candidates in various stages of development include Famitinib, Nilotinib, THE-630, DS 6157, and others.
Gastrointestinal Stromal Tumors Pipeline Analysis
The Gastrointestinal Stromal Tumors pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Gastrointestinal Stromal Tumors Market.
-
Categorizes Gastrointestinal Stromal Tumors therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Gastrointestinal Stromal Tumors drugs under development based on:
-
Stage of development
-
Gastrointestinal Stromal Tumors Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Gastrointestinal Stromal Tumors Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Gastrointestinal Stromal Tumors Licensing agreements
-
Funding and investment activities supporting future Gastrointestinal Stromal Tumors market advancement.
-
Request for a sample report @ https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Gastrointestinal Stromal Tumors Emerging Drugs
-
Famitinib: Jiangsu Hengrui Medicine
-
Nilotinib: Novartis
-
THE-630: Theseus Pharmaceuticals
-
DS 6157: Daiichi Sankyo Company
Gastrointestinal Stromal Tumors Companies
More than 25 leading companies are actively developing therapies for Gastrointestinal Stromal Tumors (GISTs), with Jiangsu Hengrui Medicine having a drug candidate that has progressed to Phase III, the most advanced stage of clinical development.
DelveInsight’s report covers around 28+ products under different phases of Gastrointestinal Stromal Tumors clinical trials like
-
Gastrointestinal Stromal Tumors Late stage Therapies (Phase III)
-
Gastrointestinal Stromal Tumors Mid-stage Therapies (Phase II)
-
Gastrointestinal Stromal Tumors Early-stage Therapies (Phase I)
-
Gastrointestinal Stromal Tumors Pre-clinical and Gastrointestinal Stromal Tumors Discovery stage Therapies
-
Gastrointestinal Stromal Tumors Discontinued & Inactive Therapies
Gastrointestinal Stromal Tumors pipeline report provides the Gastrointestinal Stromal Tumors therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Gastrointestinal Stromal Tumors Therapies and Key Gastrointestinal Stromal Tumors Companies: Gastrointestinal Stromal Tumors Clinical Trials and recent advancements
Gastrointestinal Stromal Tumors Pipeline Therapeutic Assessment
• Gastrointestinal Stromal Tumors Assessment by Product Type
• Gastrointestinal Stromal Tumors By Stage
• Gastrointestinal Stromal Tumors Assessment by Route of Administration
• Gastrointestinal Stromal Tumors Assessment by Molecule Type
Download Gastrointestinal Stromal Tumors Sample report to know in detail about the Gastrointestinal Stromal Tumors treatment market @ Gastrointestinal Stromal Tumors Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Gastrointestinal Stromal Tumors Current Treatment Patterns
4. Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Gastrointestinal Stromal Tumors Late-Stage Products (Phase-III)
7. Gastrointestinal Stromal Tumors Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gastrointestinal Stromal Tumors Discontinued Products
13. Gastrointestinal Stromal Tumors Product Profiles
14. Gastrointestinal Stromal Tumors Key Companies
15. Gastrointestinal Stromal Tumors Key Products
16. Dormant and Discontinued Products
17. Gastrointestinal Stromal Tumors Unmet Needs
18. Gastrointestinal Stromal Tumors Future Perspectives
19. Gastrointestinal Stromal Tumors Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Gastrointestinal Stromal Tumors Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/